Hikma Pharmaceuticals (OTCMKTS:HKMPF) Rating Increased to Moderate Buy at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a hold rating to a moderate buy rating in a research report released on Tuesday morning,Zacks.com reports.

Hikma Pharmaceuticals Price Performance

Shares of HKMPF opened at $24.87 on Tuesday. The stock has a 50 day moving average price of $24.48 and a 200 day moving average price of $24.92. The company has a quick ratio of 0.98, a current ratio of 1.66 and a debt-to-equity ratio of 0.46. Hikma Pharmaceuticals has a 52-week low of $21.90 and a 52-week high of $26.50.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.